ライフサイエンスコーパス: EPO

1 EPO administration (1200 U/kg) for 10 days reduced trabe

2 EPO administration alone or removal of a single Tfr2 all

3 EPO and erythroferrone reduced liver Smad1/5 phosphoryla

4 EPO induction was submaximal, as hypoxia or pharmacologi

5 EPO is a glycoprotein hormone that is essential for norm

6 EPO may provide a therapeutic option for patients with m

7 EPO treatment also reduced weight gain in ovariectomized

8 EPO treatment reduced diet-induced weight gain from 9.6

9 EPO-associated memory improvement in TRD and BD may be m

10 sTfR (HR, 1.15; 95% CI 1.03-1.28; P = 0.01), EPO (HR, 1.17; 95% CI 1.05-1.29; P = 0.004), and FGF23 (

11 HIF-1alpha, and the downstream genes GLUT-1, EPO, and VEGF-A (p < 0.05), in the absence of a signific

12 Plasma (n = 204) and CSF (n = 147) EPO levels at admission were measured by radioimmunoassa

13 IL-4, TSLP, IL-17A, EPO activity, total cell count and specific IgE and IgG1

14 Here we targeted the PHD/HIF-2/EPO axis in FOXD1 stroma-derived renal interstitial cell

15 f erythropoiesis that are driven by aberrant EPO levels.

16 orming osteoblasts and bone loss accompanies EPO-stimulated erythropoiesis in mice.

17 lasts is required for bone loss accompanying EPO-stimulated erythropoiesis.

18 tudy to evaluate the impact of epoetin alfa (EPO) on tumor outcomes when used to treat anemia in pati

19 Epoetin alfa (EPO) robustly induced bone marrow erythroferrone (Fam132

20 Although EPO treatment increased hematocrit and improved glucose

21 issue-protective EPO receptor, comprising an EPO receptor subunit (EPOR) and the common beta-chain (C

22 We have developed an EPO-R76E derivative that maintains neuroprotective funct

23 f KY1070 and Darbepoetin alfa resulted in an EPO-sparing effect.

24 hat the probability that a male will sire an EPO in an available brood is the primary source of genet

25 ire EPO, the male's probability of siring an EPO in an available brood and the number of offspring in

26 Serum and renal IGF-1 and EPO were significantly increased in UPI/OIR compared to

27 (HR, 1.08; 95% CI 0.96-1.20; P = 0.19), and EPO (HR, 1.10; 95% CI 0.99-1.22; P = 0.08) with mortalit

28 ating EPC and levels of VEGF, HIF-1alpha and EPO were significantly higher after exercise (P < 0.05).

29 e transferrin receptor (sTfR; B = 0.33), and EPO (B = 0.28) were associated with FGF23 level, indepen

30 on and thus regulation of HIF-2 activity and EPO production under hypoxia or conditions of pharmacolo

31 We found that both cibinetide and EPO ameliorated the clinical course of experimental coli

32 t modulators of EPO and EPOR expression, and EPO's biological effects.

33 ationship between blood levels of MIR122 and EPO in mice with acute pancreatitis or steatohepatitis,

34 weight control and glucose sensitivity, and EPO receptor gene expression was reduced in wild-type fe

35 0.008) after adjustment for TSAT, sTfR, and EPO levels.

36 eticulum (ER) compartment and that SURF4 and EPO physically interact.

37 hematocrit levels and BP as substantially as EPO.

38 the anemia, the combination of Tmprss6-ASO + EPO or Tmprss6-ASO + Tfr2 single-allele deletion produce

39 tenin signaling, resulted in cell-autonomous EPO transcription in mouse and human hepatocytes.

40 significant proportion of patients becoming EPO resistant over time explains the medical need to def

41 ibly commit to an erythroid fate well before EPO acts, risking inefficiency if these progenitors are

42 mortality and 48% of the association between EPO and mortality (indirect effect P < 0.05 for all anal

43 ages of DR, and positive correlation between EPO serum concentration and clinical stages of PDR, sugg

44 To investigate the relationship between EPO/ERFE and matriptase-2, we show that EPO injection in

45 uction of EPO levels in the host or blocking EPO-EPOR signaling may be an effective strategy to impro

46 Local expression of both EPO and its receptor is upregulated upon injury or stres

47 latory effects on eosinophils as assessed by EPO and IL-8 release and eosinophil chemotaxis toward SE

48 ficial effects on RBC production mediated by EPO or Tfr2 deletion.

49 KO mice counteracts hepcidin suppression by EPO, we generated double KO Bmp6-Tmprss6 KO mice.

50 eptor and CD131 on antigen-presenting cells, EPO induced the secretion of active TGFbeta by antigen-p

51 inocrit expressed the least Neu5Gc, and CIGB-EPO showed the greatest variety of high-mannose-phosphat

52 and a development product, called here CIGB-EPO, were compared to the originator product, Eprex.

53 The circulating EPO level was also constitutively higher in mice lacking

54 Studies using EPO-deficient mice confirm EPO serves as a major enzymatic source for protein carba

55 Hypoxia-inducible factor 2 (HIF-2) controls EPO synthesis in the kidney and liver and is regulated b

56 Conversely, EPO-initiated signals facilitated Treg proliferation by

57 Plasma and CSF EPO levels also correlated positively with coma duration

58 Plasma and CSF EPO levels did not differ in children with vs those with

59 aptopril reduced radiation-induced cytokines EPO, G-CSF, and SAA in the plasma.

60 armacologic downregulation of kidney-derived EPO prevented spontaneous Treg generation.

61 armacologic downregulation of kidney-derived EPO reduced the expression of TGFbeta mRNA and abrogated

62 Subsequent treatment with low-dose EPO triggered robust RBC production in both models.

63 range of oxygen responsive target genes (eg, EPO and VEGF), certain members of the oxygen/2-oxoglutar

64 These molecules activate endogenous EPO gene expression in diseased kidneys and are being de

65 In conclusion, endogenous EPO-Epor signaling in osteoblasts is important in bone r

66 As a mimetic of endogenous EPO (eEPO), rHuEPO augments the oxygen carrying capacity

67 used a defect in the secretion of endogenous EPO under conditions mimicking hypoxia, ruling out an ar

68 Our engineered EPO molecule was mutated to weaken its affinity for EPO-

69 evidence that blocking erythropoietin (EPO)-EPO receptor (R) signaling promotes homing to BM and ear

70 Recombinant human erythropoetin (EPO) is an important biopharmaceutical mainly used for t

71 Erythropoietin (EPO) and its receptor are expressed in a wide variety of

72 Erythropoietin (EPO) and its receptor are highly expressed in the develo

73 Erythropoietin (EPO) increases neuroplasticity and reduces cognitive dif

74 Erythropoietin (EPO) is a key regulator of erythropoiesis.

75 Erythropoietin (EPO) is one of the main therapeutics used to treat anemi

76 Erythropoietin (EPO) is one of the systemic angiogenic factors, and its

77 Erythropoietin (EPO) is the cytokine that regulates red blood cell produ

78 Erythropoietin (EPO) may be a beneficial tissue-protective cytokine.

79 Erythropoietin (EPO) production in the kidney is regulated by the oxygen

80 Erythropoietin (EPO) provides the major survival signal to maturing eryt

81 Erythropoietin (EPO) regulates erythropoiesis by binding to erythropoiet

82 Erythropoietin (EPO) stimulates erythroid differentiation and maturation

83 cose transporter 1 (GLUT-1), erythropoietin (EPO), and vascular endothelial growth factor A (VEGF-A)

84 and kidney VEGF, IGF-1, and erythropoietin (EPO) were determined.

85 tor 1-alpha (HIF-1alpha) and erythropoietin (EPO) were measured as potential mechanisms for exercise-

86 ovide evidence that blocking erythropoietin (EPO)-EPO receptor (R) signaling promotes homing to BM an

87 Blood erythropoietin (EPO) increases primarily to hypoxia.

88 sis is acutely stimulated by erythropoietin (EPO) to favor iron supply to maturing erythroblasts.

89 n response to stimulation by erythropoietin (EPO).

90 -ligand system, the cytokine Erythropoietin (EPO) and its receptor (EpoR), to dimerize EpoR ectodomai

91 tion (R150Q) in the cytokine erythropoietin (EPO).

92 h in vivo to the anemia drug erythropoietin (EPO), to direct its activity to EPO receptors (EPO-Rs) o

93 emia, splenomegaly, elevated erythropoietin (EPO) levels, and extramedullary erythropoiesis in a proc

94 trends in hemoglobin (Hgb), erythropoietin (EPO) dose, intravenous (IV) iron dose, ferritin, transfe

95 The investigation of erythropoietin (EPO) has expanded to include potential nonhematopoietic

96 We found that expression of erythropoietin (EPO) in a HEK293S N-acetylglucosaminyltransferase I (GnT

97 Studies of the regulation of erythropoietin (EPO) production by the liver and kidneys, one of the cla

98 higher circulating levels of erythropoietin (EPO) stimulate the expression and concomitant cleavage o

99 t the topical application of erythropoietin (EPO) to cutaneous wounds in rats and mice with experimen

100 is and is the main source of erythropoietin (EPO), an oxygen-sensitive glycoprotein that is essential

101 they are the main source of erythropoietin (EPO).

102 (HIF)-mediated induction of erythropoietin (EPO).

103 had increased phosphorylated erythropoietin (EPO) receptor and phosphorylated STAT-5 relative to matc

104 Elevated endogenous plasma erythropoietin (EPO) levels have been associated with protection from ac

105 tors of red cell production, erythropoietin (EPO) and its cell surface receptor (EPO receptor [EPOR])

106 Recombinant erythropoietin (EPO) and iron substitution are a standard of care for tr

107 (ERFE) expression and serum erythropoietin (EPO) levels.

108 We find that erythropoietin (EPO) and stromal derived factor-1alpha can attract PCa i

109 udies have demonstrated that erythropoietin (EPO) has extensive nonhematopoietic biological functions

110 d human models, we show that erythropoietin (EPO) signaling, together with the GATA1 transcriptional

111 hese factors were run, three erythropoietin (EPO) genetic variants in linkage disequilibrium (LD) wit

112 erythroblasts in response to erythropoietin (EPO) and acts in the liver to prevent hepcidin stimulati

113 te the cellular responses to erythropoietin (EPO) in different tissues.

114 revealed hypersensitivity to erythropoietin (EPO).

115 Wild-type erythropoietin (EPO) is promising for neuroprotection, but its therapeut

116 eceptor subtype (LPA3) under erythropoietin (EPO) induction.

117 increase erythropoiesis (by erythropoietin [EPO] administration or modulating the ability of transfe

118 the developing nervous system, and exogenous EPO therapy is potentially neuroprotective, however the

119 , an effect that was overcome with exogenous EPO administration.

120 e adult liver retains the ability to express EPO, and we discovered here new players of this transcri

121 ecule was mutated to weaken its affinity for EPO-R, but its avidity for RBC precursors was rescued vi

122 These data support a role for EPO in regulating the survival, proliferation, and diffe

123 A black box warning for EPO therapy and concerns about negative side effects rel

124 Furthermore, EPO directly inhibited conventional T cell proliferation

125 Thus, we identified new hepatic EPO regulation mechanism stimulating erythropoiesis.

126 ed the renal expression of the heterodimeric EPO receptor/CD131 complex, which is required for the ti

127 cal implications of iron deficiency and high EPO levels in the general population, and the potential

128 ly elevated hepcidin in the presence of high EPO levels, a role is suggested for matriptase-2 in EPO-

129 d that functional iron deficiency and higher EPO levels were each associated with an increased risk o

130 ociations between iron deficiency and higher EPO levels with mortality, and the potential mediating r

131 However, it remains unclear how EPO functions to support the neural retina.

132 However, EPO increased the expression of Nfatc1 and ephrinB2 but

133 However, EPO or Tfr2 single-allele deletion alone, respectively,

134 tudies, clinical trials of recombinant human EPO (rHuEPO) have been started in children with CM.

135 combination of KY1070 and recombinant human EPO improved the erythroid response compared with either

136 Transgenic mice with hypoactive EPO receptor (EPOR) signaling (hWtEPOR) were compared wi

137 activities and survival effects of identical EPO and CEPO doses in rat models of clinically relevant

138 els, a role is suggested for matriptase-2 in EPO-mediated hepcidin repression.

139 uppression in ERFE-treated Huh7 cells and in EPO-treated mice.

140 ale mice, we observed a gender difference in EPO effects in weight control.

141 stone H3 lysine 4 dimethylation (H3K4me2) in EPO treated and control fetal neural progenitor cells, i

142 e analysis demonstrated a 2-fold increase in EPO expression in all S-HB, while 4/5 showed either Hypo

143 Moreover, systemic reduction in EPO levels by hyperbaric oxygen (HBO) used in a preclini

144 rated and resulted in transient reduction in EPO with encouraging engraftment rates and kinetics.

145 phB4 signaling may play an important role in EPO-mediated bone formation.

146 een functional iron deficiency and increased EPO levels and death.

147 of HIF-PHD by roxadustat leads to increased EPO production, better iron absorption, and amelioration

148 ar cells but paradoxically further increases EPO.

149 nvestigate this apparent hypoxia-independent EPO regulation, we assessed two sickle cell disease (SCD

150 phB4 knockdown through EphB4 shRNA inhibited EPO-mediated osteoblastic phenotypes.

151 able and selectable readout of intracellular EPO levels and performed a genome-scale CRISPR screen th

152 n-induced AKI superimposed on CKD (5000 U/kg EPO or CEPO; three subcutaneous injections) and ischemia

153 ls and male versus female animals (1000 U/kg EPO or CEPO; three subcutaneous injections).

154 Laboratory EPO serum levels were determined, and they were correlat

155 to data from a previous report, mice lacking EPO receptor (EPOR) expression on nonerythroid cells (EP

156 e that the pre-EPO module is coupled to late EPO-dependent erythropoiesis by megakaryocyte (Mk) signa

157 Both MP types effectively loaded EPO-R76E and achieved sustained release, providing detec

158 Mean EPO and vitamin D dose and serum PTH levels remained hig

159 lined from 11.5 to 11.0 g/dl (P<0.001), mean EPO dose declined from 20,506 to 14,777 U/wk (P<0.001),

160 response of two polymeric microparticle (MP) EPO-R76E sustained release formulations based on convent

161 obular species in the eastern Pacific Ocean (EPO).

162 ruption of SURF4 resulted in accumulation of EPO in the endoplasmic reticulum (ER) compartment and th

163 l, can potentiate the accelerating action of EPO on the healing of the burn injury.

164 ess understood is the nonerythroid action of EPO, including metabolic regulation of fat accumulation

165 equently triggering significant apoptosis of EPO-dependent EPs.

166 the pre-EPO module, leading to apoptosis of EPO-sensitive EPs.

167 The highest average concentration of EPO in serum (9.95 mIU/ml) was determined in the group o

168 The average concentration of EPO in serum in the group of patients with diabetes with

169 ignificantly elevated serum concentration of EPO in the advanced stages of DR, and positive correlati

170 The lowest average concentration of EPO in the serum (6.90 mIU/ml) was found in the control

171 Concentration of EPO was assessed by ELISA method.

172 Furthermore, mice with targeted deletion of EPO receptor in white adipose tissue exhibited sex-diffe

173 ed that PPS and PLGA MP-mediated delivery of EPO-R76E provided therapeutic protection.

174 accumulation and extracellular depletion of EPO.

175 well studied, the molecular determinants of EPO secretion remain unknown.

176 However, high doses of EPO are associate with adverse effects, including thromb

177 proach may allow higher restorative doses of EPO without platelet-mediated side effects, and also may

178 ic and transcriptional changes downstream of EPO signaling in neural cells are not well understood.

179 sting a role for REST and NRF1 downstream of EPO signaling.

180 n this study, we investigated the effects of EPO on the communication between osteoclasts and osteobl

181 l role in mediating the metabolic effects of EPO.

182 ased erythroid development and expression of EPO and ERFE in extrahepatic tissues independent of TFR'

183 ant DNA technology allowed the expression of EPO-encoding genes in several eukaryotic hosts to produc

184 us core-fucosylated Man5GlcNAc2 glycoform of EPO in the FUT8-overexpressed HEK293S GnT I(-/-) cell li

185 cytes in Tg mice, suggesting independence of EPO signaling in mature osteoblasts, osteoclasts, and ad

186 ms for hypoxia-inducible factor induction of EPO expression, and within erythroid progenitors EPOR en

187 tor 2-mediated (HIF-2-mediated) induction of EPO in peritubular interstitial fibroblast-like cells, w

188 The expression level of EPO mRNA was elevated in the kidney and liver but not in

189 tagonist of MIR122 increased blood levels of EPO, reticulocytes, and hemoglobin.

190 ined release, providing detectable levels of EPO-R76E at the injection site in the eye in vivo for at

191 the contribution of AQP3 to the mechanism of EPO action on the healing of burn wounds in the skin of

192 identified SURF4 as an important mediator of EPO secretion.

193 including previously identified mediators of EPO signaling (STAT5, STAT3), and novel factors such as

194 ncover new clinically relevant modulators of EPO and EPOR expression, and EPO's biological effects.

195 associated with a reduction in the number of EPO-producing renal interstitial cells.

196 ation of residue-specific glycan profiles of EPO was established.

197 s delineate the protolerogenic properties of EPO in inhibiting conventional T cells while simultaneou

198 Such a systemic reduction of EPO in the host enhanced myeloid differentiation and imp

199 studies indicate that systemic reduction of EPO levels in the host or blocking EPO-EPOR signaling ma

200 Though the transcriptional regulation of EPO has been well studied, the molecular determinants of

201 types also contributes to the regulation of EPO production.

202 LGA and PPS MPs enabled sustained release of EPO-R76E, providing therapeutic benefits including reduc

203 expression results in increased secretion of EPO, suggesting a new strategy for more efficient produc

204 tor that mediates the efficient secretion of EPO.

205 e cells, which serve as the cellular site of EPO synthesis in the kidney.

206 cess control and release testing strategy of EPO.

207 chanisms by which the genetic variability of EPO affects the mortality of T2D patients may provide po

208 DSS-exposed mice treated with cibinetide or EPO displayed preserved tissue integrity due to reduced

209 d eosinophil activation (CD11b expression or EPO/IL-8 release), mCD48 (flow cytometry), sCD48 (ELISA)

210 increase in mice subjected to hemorrhage or EPO therapy, that ERFE acts on hepatocytes to suppress h

211 We use this assay to show that blood loss or EPO administration increases serum ERFE concentrations i

212 ts; data were thus analyzed for 69 patients (EPO: n = 35, saline: n = 34).

213 nic protein (ECP) and eosinophil peroxidase (EPO) (P < .05), while IFABP was positively related to th

214 Here we show eosinophil peroxidase (EPO), an abundant granule protein released by activated

215 Plasma EPO levels correlated positively with markers of endothe

216 High endogenous plasma EPO levels are associated with prolonged coma duration a

217 ll anaemia (homozygous HBBE6V; HbSS), plasma EPO is elevated due to hemolytic anaemia-related hypoxia

218 in level, a 1-natural-log increase in plasma EPO level was associated with a 1.74-fold increase in mo

219 llele of SNP rs60684937 and increased plasma EPO (n = 567, combined P = 5.5 x 10 - 8 adjusted for hae

220 atological changes with elevations of plasma EPO and circulating reticulocytes following single oral

221 In conclusion, we demonstrate that plasma EPO elevation with hydroxyurea in SCD is independent of

222 cohorts for genetic associations with plasma EPO, by prioritizing 237,079 quantitative trait loci for

223 -functional antibody fusion exhibited potent EPO and GCSF agonist activities.

224 for the first time, demonstrate that the pre-EPO module is coupled to late EPO-dependent erythropoies

225 eta signaling in normal mice boosted the pre-EPO module, leading to apoptosis of EPO-sensitive EPs.

226 organized hematopoiesis by expanding the pre-EPO pool of progenitor cells and consequently triggering

227 ffects than JAK2 R1063H and caused prolonged EPO-induced phosphorylation of JAK2/STAT5 via EPOR.

228 aling via ephrinB2-Fc significantly promoted EPO-mediated osteoblastic differentiation in ST2 cells.

229 selectively activates the tissue-protective EPO receptor, comprising an EPO receptor subunit (EPOR)

230 nanomolar concentrations, STS-E412 provided EPO-like cytoprotective effects in primary neuronal cell

231 poietin (EPO) and its cell surface receptor (EPO receptor [EPOR]) have been intensely studied.

232 O), to direct its activity to EPO receptors (EPO-Rs) on red blood cell (RBC) precursors and prevent i

233 tional murine transplant models, recombinant EPO administration prolonged heart allograft survival, w

234 for more efficient production of recombinant EPO.

235 PHDs in REPC pool size regulation and renal EPO output.

236 and the role of the PHD/HIF-2 axis in renal EPO-producing cell (REPC) plasticity is unclear.

237 erstitial cellular crosstalk modulates renal EPO production under conditions of epithelial HIF activa

238 Moreover, suppression of renal EPO production was associated with increased glucose upt

239 Compared with saline, EPO was associated with mood-independent memory improvem

240 es not result in discernible change in serum EPO or hemoglobin (n = 60).

241 Using a combination of studies we now show EPO uses plasma levels of the pseudohalide thiocyanate (

242 of broods available to a focal male to sire EPO, the male's probability of siring an EPO in an avail

243 established, mice were treated with solvent, EPO or the selective IRR agonist cibinetide.

244 underscore the potential for gender specific EPO action beyond erythropoiesis.

245 sured circulating parameters of iron status, EPO levels, and plasma total FGF23 levels.

246 ntrolled, prospective cohort clinical study, EPO administration at doses used to correct anemia augme

247 In summary, EPO-mediated protein carbamylation is promoted during al

248 nvestigate whether the ability to synthesize EPO is a general functional feature of pericytes, we use

249 rmore suggest that the ability to synthesize EPO may represent a functional feature of pericytes in t

250 ound that pericytes in the brain synthesized EPO in mice with genetic HIF activation and were capable

251 The terminal plasma half-life of targeted EPO was approximately 28.3 h in transgenic mice vs. appr

252 huGYPA transgenic mice dosed with targeted EPO exhibited elevated RBC levels, with only minimal pla

253 re, in vivo assays clearly demonstrated that EPO efficiently induces new bone formation in the alveol

254 Furthermore, we found that EPO is detectable in cyst fluid from S-HB (n = 14), whil

255 We found that EPO slightly promotes osteoblastic differentiation with

256 Herein we test the hypothesis that EPO, a hormone predominantly produced by the adult kidne

257 ween EPO/ERFE and matriptase-2, we show that EPO injection induces Erfe messenger RNA expression but

258 Animal results show that EPO-releasing cancer trap attracted large number of circ

259 The EPO concentration in serum was elevated in the group of

260 The EPO mutant is less effective at stimulating erythroid ce

261 ased phosphorylation of EPOR, CD131, and the EPO-associated signaling molecules JAK2 and AKT in HEK29

262 cutoff (1,337 deaths) was 17.2 months in the EPO and 17.4 months in the best standard of care group (

263 predict both the areas of importance in the EPO, that are already known for this species, and the mo

264 xpression of HIF target genes, including the EPO gene.

265 induction, and suggest that manipulating the EPO/EPO receptor signaling axis could be exploited to pr

266 ignaling only in the specific context of the EPO receptor (EPOR).

267 In vitro, in a manner dependent on the EPO receptor and CD131 on antigen-presenting cells, EPO

268 Surprisingly, the EPO R150Q mutant shows only a mild reduction in affinity

269 Our findings provide evidence that the EPO gene is an independent predictor of mortality in pat

270 We found that the EPO produced from the FUT8 knockdown cell line was the p

271 While the EPO mutant can stimulate effectors such as STAT5 to a si

272 thropoietin (EPO), to direct its activity to EPO receptors (EPO-Rs) on red blood cell (RBC) precursor

273 tic breast cancer, were randomly assigned to EPO 40,000 IU subcutaneously once a week or best standar

274 ays and gene expression profiles compared to EPO.

275 ariation at SNP rs60684937 may contribute to EPO regulation through a cAMP-dependent protein kinase A

276 Exposure of UCB CD34(+) HSPC to EPO inhibits their migration and enhances erythroid diff

277 evidence for a sex-differential response to EPO in weight control in mice and underscore the potenti

278 esting that the sex-differential response to EPO was associated with estrogen.

279 mice do not suppress hepcidin in response to EPO.

280 nt, fail to suppress hepcidin in response to EPO.

281 ors, improves the hepcidin responsiveness to EPO in Tmprss6 KO mice.

282 Thus, CEPO therapy may be superior to EPO in improving outcomes in common forms of clinical AK

283 We found that topical EPO treatment of the burns accelerated their healing thr

284 ial constituent of the ECM, into the topical EPO-containing gel, can potentiate the accelerating acti

285 STS-E412 triggered EPO receptor phosphorylation in human neuronal cells.

286 Studies using EPO-deficient mice confirm EPO serves as a major enzymat

287 Activation of the VHL-HIF1a-VEGF-EPO pathway in the adult retina led to long-term neovasc

288 n vivo selectivity depended on the weakening EPO mutation, fusion to the RBC-specific antibody, and e

289 artial remission were randomized to 8 weekly EPO (40,000 IU) or saline infusions in a double-blind, p

290 Here, we combined Tmprss6-ASO with EPO administration or removal of a single Tfr2 allele in

291 delineate epigenetic changes associated with EPO signaling, we compared histone H3 lysine 4 dimethyla

292 Renal interstitial cells with EPO-producing capacity are poorly characterized, and the

293 Renal interstitial cells with EPO-producing capacity were entirely derived from FOXD1-

294 Compared with EPO therapy in the other AKI groups, CEPO therapy induce

295 Compared with EPO therapy, CEPO therapy induced greater improvements i

296 can be harnessed to work in complement with EPO-R76E or other drugs for neuroprotection in the setti

297 g with PBS treatment and 3.3 +/- 2.1 g with EPO treatment).

298 s oxygen sensors and respond to hypoxia with EPO synthesis.

299 RBC) precursors and prevent interaction with EPO-Rs on nonerythroid cells, such as platelets.

300 ocitrulline is shown to be co-localized with EPO within human asthmatic airways.